2SPD-033 Evaluation of docetaxel in low and high burden metastatic hormone sensitive prostate cancer

Background and importanceAddition of docetaxel to hormonal treatment in low and high burden metastatic hormone sensitive prostate cancer (mHSPC) has raised important issues. There are studies suggesting increased overall survival (OS) in high burden disease and lack of benefit for low volume of meta...

Full description

Saved in:
Bibliographic Details
Published in:European journal of hospital pharmacy. Science and practice 2021-03, Vol.28 (Suppl 1), p.A8-A8
Main Authors: Gil-Sierra, MD, Briceño-Casado, MDP, Sanchez-Hidalgo, M, Alarcon De La Lastra-Romero, C, De La Calle-Riaguas, B, Dominguez-Cantero, M, Alegre-Del Rey, EJ
Format: Article
Language:English
Subjects:
Conflicts of interest
Metastasis
Prostate cancer
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Background and importanceAddition of docetaxel to hormonal treatment in low and high burden metastatic hormone sensitive prostate cancer (mHSPC) has raised important issues. There are studies suggesting increased overall survival (OS) in high burden disease and lack of benefit for low volume of metastases.Aim and objectivesTo perform a systematic search and methodological evaluation of subgroup analyses about the use of docetaxel in mHSPC according to volume of metastatic disease (VMD).Material and methodsA systematic search in Pubmed was conducted up to 25 September 2020. The following search strategy was used in the ‘Clinical Queries/Narrow’ tool: (Therapy/Narrow[filter]) AND (docetaxel AND prostate cancer AND hormone sensitive). Randomised clinical trials (RCTs) with subgroup analysis regarding VMD for OS were included. The rest of the review results were excluded. Two methodologies were used. One evaluated the heterogeneity of the subgroups (p
ISSN:2047-9956
2047-9964
DOI:10.1136/ejhpharm-2021-eahpconf.16